| __timestamp | Perrigo Company plc | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2613100000 | 125883000 |
| Thursday, January 1, 2015 | 2891500000 | 69036000 |
| Friday, January 1, 2016 | 3228800000 | 72700000 |
| Sunday, January 1, 2017 | 2966700000 | 105700000 |
| Monday, January 1, 2018 | 2900200000 | 198700000 |
| Tuesday, January 1, 2019 | 3064100000 | 117600000 |
| Wednesday, January 1, 2020 | 3248100000 | 108100000 |
| Friday, January 1, 2021 | 2722500000 | 122500000 |
| Saturday, January 1, 2022 | 2996200000 | 146700000 |
| Sunday, January 1, 2023 | 2975200000 | 257500000 |
Data in motion
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. From 2014 to 2023, Perrigo Company plc consistently reported a higher cost of revenue compared to United Therapeutics Corporation. Perrigo's cost of revenue peaked in 2020 at approximately $3.25 billion, reflecting a 24% increase from 2014. In contrast, United Therapeutics saw a more modest rise, with its cost of revenue reaching around $258 million in 2023, marking a significant 104% increase from its 2015 low.
This disparity highlights Perrigo's larger scale of operations and possibly more extensive product lines. Meanwhile, United Therapeutics' focused approach may contribute to its lower cost base. These insights are pivotal for investors and stakeholders aiming to understand the financial dynamics and operational efficiencies of these two pharmaceutical giants.
Eli Lilly and Company vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
United Therapeutics Corporation vs Perrigo Company plc: Strategic Focus on R&D Spending
Analyzing Cost of Revenue: Grifols, S.A. and Perrigo Company plc
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.